Acrivon Therapeutics, Inc. Common Stock
Symbol: ACRV (NASDAQ)
1.64
▲ (6.49%) 0.100
Company Description:
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.
Key Stats
- Today's Open: $1.53
- Today's High: $1.669
- Today's Low: $1.51
- Today's Volume: 306.15K
- Yesterday Close: $1.54
- Yesterday High: $1.62
- Yesterday Low: $1.51
- Yesterday Volume: 330.41K
- Last Min Volume: 50
- Last Min High: $1.64
- Last Min Low: $1.64
- Last Min VWAP: $1.64
Company Profile
- Name: Acrivon Therapeutics, Inc. Common Stock
- Website: https://www.acrivon.com
- Listed Date: 2022-11-15
- Location: WATERTOWN, MA
- Market Status: Active
- CIK Number: 0001781174
- SIC Code: 2834
- SIC description: PHARMACEUTICAL PREPARATIONS
- Market Cap: $52.22M
- Round Lot: 100
- Outstanding Shares: 31.46M
- Asset Type: CS
RECENT FILINGS FOR ACRV
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-09-05 | 8-K | View |
| 2025-08-25 | 4 | View |
| 2025-08-18 | 4 | View |
| 2025-08-18 | 4 | View |
| 2025-08-18 | 4 | View |
| 2025-08-18 | 4 | View |
| 2025-08-18 | 4 | View |
| 2025-08-13 | 10-Q | View |
| 2025-08-13 | 8-K | View |
| 2025-08-13 | SCHEDULE 13G/A | View |
| 2025-08-05 | 4 | View |
| 2025-07-21 | 4 | View |
| 2025-06-17 | 4 | View |
| 2025-06-17 | 4 | View |
| 2025-06-17 | 4 | View |
| 2025-06-17 | 4 | View |
| 2025-06-17 | 4 | View |
| 2025-06-17 | 4 | View |
| 2025-06-17 | 4 | View |
| 2025-06-13 | 8-K | View |
Latest News on ACRV